Source comparison
CJC-1295 no DAC & Ipamorelin Interactions: Research Applications Comparison
Peak GH Pulse Amplitude Moderate (2–3× baseline) Moderate (2–4× baseline) High (5–8× baseline synergistic) Stacking produces non-additive amplification through dual-pathway activation. This is the primary advantage Cortisol & Prolactin Elevation Minimal Minima
This comparison does not assign a generated winner or score.
- Peak GH Pulse Amplitude
- Moderate (2–3× baseline)
- Moderate (2–4× baseline)
- High (5–8× baseline synergistic)
- Stacking produces non-additive amplification through dual-pathway activation. This is the primary advantage
- Cortisol & Prolactin Elevation
- Minimal
- Minimal (most selective GHRP)
- Minimal (Ipamorelin's selectivity preserved)
- Ipamorelin's GHS-R1a selectivity prevents the cortisol spikes seen with GHRP-2 or GHRP-6. Critical for repeated dosing
- Dose Frequency for Sustained Effect
- 2–3× daily (short half-life)
- 2–3× daily or 1× daily before sleep
- Neither peptide supports once-daily sustained GH elevation alone. Stacking doesn't change half-life
- Receptor Desensitization Risk
- Low with 3–4 hour intervals
- Low if dosing intervals maintained
- Dual-pathway activation doesn't bypass desensitization. Refractory periods still required
- Cost per Equivalent GH Pulse
- Moderate
- Lower per unit GH elevation (synergy)
- Synergistic stacking produces more GH per mcg of peptide used. Better research efficiency
- The comparison makes the mechanism clear: CJC-1295 no DAC & Ipamorelin interactions aren't about one peptide being better than the other. They're about activating two separate signaling cascades that converge on the same endpoint. Research applications requiring maximal GH pulse amplitude consistently favour stacked administration because the synergy delivers results neither peptide achieves independently. For labs exploring growth hormone dynamics, precision-synthesized CJC 1295 NO DAC and Ipamorelin provide the molecular specificity required for reproducible research outcomes.